Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Adv...

    2026-04-01

    Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Advanced Cell Biology

    Introduction: Principle and Setup of Y-27632 Dihydrochloride

    Y-27632 dihydrochloride is a highly potent Rho-associated protein kinase inhibitor (ROCK inhibitor), specifically targeting the catalytic domains of ROCK1 (IC50 ≈ 140 nM) and ROCK2 (Ki ≈ 300 nM). This selective ROCK1 and ROCK2 inhibitor disrupts the Rho/ROCK signaling pathway, inhibiting Rho-mediated stress fiber formation, modulating cell cycle progression from G1 to S phase, and interfering with cytokinesis. Due to its high degree of selectivity—over 200-fold more potent against ROCK than kinases such as PKC, MLCK, and PAK—Y-27632 dihydrochloride is widely recognized as a cell-permeable ROCK inhibitor for cytoskeletal studies, stem cell viability enhancement, and tumor invasion and metastasis suppression.

    Supplied by APExBIO (Y-27632 dihydrochloride), this small molecule offers excellent solubility profiles (≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, ≥52.9 mg/mL in water) and is stable when stored desiccated at 4°C or below. Its robust performance in cell proliferation assays, Rho kinase signaling pathway studies, and tumor invasion models makes it an indispensable tool for modern cell and cancer biology.

    Workflow Optimization: Stepwise Protocols for Y-27632 Dihydrochloride Applications

    1. Preparation and Storage

    • Stock Solution Preparation: Dissolve Y-27632 dihydrochloride in DMSO (recommended for maximum solubility and stability) at a concentration of 10–50 mM. Vortex until fully dissolved.
    • Aliquot and Storage: Divide stock into single-use aliquots, store at –20°C, and avoid repeated freeze-thaw cycles. Protect from long-term solution storage to preserve potency.
    • Working Solution: Dilute to desired final concentration (commonly 10–50 μM for cell culture) in appropriate culture medium immediately before use.

    2. In Vitro Applications

    • Stem Cell Culture: Supplement human or mouse pluripotent stem cell (PSC) cultures with 10 μM Y-27632 dihydrochloride during passaging or single-cell dissociation to enhance viability and minimize apoptosis. This is especially effective for human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs).
    • Prostatic Smooth Muscle Cell Proliferation: For primary human and rat prostatic smooth muscle cells, add 10–30 μM Y-27632 dihydrochloride to modulate proliferation and cytoskeletal organization. Monitor Rho-mediated stress fiber formation via phalloidin staining or fluorescence microscopy.
    • Cell Proliferation & Viability Assays: Treat adherent or suspension cells with Y-27632 dihydrochloride and assess proliferation by MTT, CCK-8, or BrdU incorporation assays. Typical incubation time ranges from 24–72 hours, depending on cell type and experimental endpoint.

    3. In Vivo Models

    • Tumor Invasion and Metastasis Suppression: Administer Y-27632 dihydrochloride via intraperitoneal injection (IP) in animal models, commonly at 5–30 mg/kg body weight, to study its impact on cancer metastasis and pre-carcinoma treatment. Monitor tumor spread using bioluminescence imaging or histopathological analysis.
    • ROCK1 and ROCK2 Kinase Activity Assay: Quantify kinase inhibition in tissues by measuring phosphorylation of downstream targets (e.g., MYPT1) via Western blot or ELISA.

    Advanced Applications and Comparative Advantages

    Y-27632 dihydrochloride’s broad utility is reflected in its transformative impact across multiple research domains:

    • Stem Cell Viability Enhancement: By inhibiting ROCK-dependent apoptosis during cell dissociation, Y-27632 dihydrochloride dramatically increases the survival rate of hESCs/iPSCs post-passaging. Studies routinely report a 2–5-fold improvement in single-cell survival compared to controls, enabling reliable expansion and genetic manipulation workflows (see comparative workflow analysis).
    • Tumor Invasion and Metastasis Suppression: Y-27632 dihydrochloride effectively reduces invasion and metastatic spread in solid tumor models, particularly in pre-carcinoma stages where ROCK2 inhibition is critical. Quantitative data from animal studies indicate reductions in metastatic foci by up to 70% with optimized dosing regimens (systems biology perspective).
    • Cytoskeletal Dynamics and Rho/ROCK Pathway Interrogation: The inhibitor allows precise dissection of Rho kinase signaling in cancer biology and cell migration. Its selectivity ensures minimal off-target effects, making it a gold standard for cytoskeletal organization research (mechanistic and regenerative medicine insights).
    • Synergy with Genetic or Pharmacologic Interventions: Y-27632 dihydrochloride can be combined with DDX3X pathway modulation, as highlighted in the recent study (Cell Death & Disease, 2025), which elucidates the interplay between cytoskeletal regulation and metabolic vulnerability in KRAS-driven lung cancer. This integration enables deeper exploration of adjuvant therapeutic strategies.

    Comparatively, other small molecule ROCK inhibitors often lack the selectivity, solubility, or reproducibility offered by Y-27632 dihydrochloride. Its robust performance in both 2D and 3D culture, low cytotoxicity, and compatibility with high-throughput screening platforms further distinguish it in the field.

    Troubleshooting and Optimization Tips

    • Solubility Issues: If precipitation is observed upon dilution in aqueous medium, ensure DMSO stock is fully dissolved before dilution. For sensitive cell types, limit final DMSO concentration to ≤0.1%.
    • Batch Variability: Use high-purity, research-grade Y-27632 dihydrochloride from trusted suppliers such as APExBIO to minimize variability. Always verify batch-specific Certificate of Analysis for purity and potency.
    • Optimal Storage: Prolonged storage of working solutions can lead to degradation. Aliquot and store desiccated at –20°C or below, and avoid repeated freeze-thaw cycles. For maximal stability, prefer solid form over solution for long-term storage.
    • Cytotoxicity at High Concentrations: Excessive concentrations (>50 μM) may induce off-target effects or cytotoxicity. Always titrate starting from 5–10 μM and adjust based on cell type sensitivity and experimental endpoint.
    • Assay Interference: For kinase activity or phospho-protein readouts, include appropriate vehicle and untreated controls to distinguish specific ROCK inhibition from DMSO-dependent effects.

    For additional troubleshooting and scenario-driven experimental guidance, see the comprehensive resource "Y-27632 dihydrochloride (SKU A3008): Solving Real-World Assay Challenges", which complements this protocol-focused overview by addressing laboratory hurdles and validated best practices.

    Future Outlook: Y-27632 Dihydrochloride in Translational Research

    The landscape of ROCK kinase inhibitor for cell proliferation studies, stem cell engineering, and cancer metastasis research is rapidly evolving. As highlighted in the reference study (Dian et al., 2025), the integration of ROCK inhibition with novel genetic and metabolic targets (such as DDX3X) opens new avenues for anti-tumor strategies, particularly in drug-resistant contexts like KRAS-driven lung cancer. The ability of Y-27632 dihydrochloride to modulate cell cycle G1 to S phase regulation, promote stem cell engraftment, and suppress invasive phenotypes positions it as an ideal candidate for combination therapies and precision modeling of disease mechanisms.

    Emerging advances in high-throughput screening, 3D organoid culture, and in vivo imaging are likely to further expand the utility of this small molecule ROCK inhibitor. As research continues to bridge the gap between fundamental cell biology and clinical translation, APExBIO’s Y-27632 dihydrochloride will remain a cornerstone for dissecting the complexities of the Rho/ROCK signaling pathway, cytoskeletal dynamics, and cell fate decisions.

    For detailed protocols, product specifications, and ordering information, visit the Y-27632 dihydrochloride product page.